Press Releases

Press Releases

Presage Biosciences Appoints David Johnson to Board of Directors
June 3, 2016 | Seattle, Wash. Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drugs and combinations directly in patient tumors, announced today the appointment of David Johnson to its board of directors. Johnson has more than two decades of experience in the biopharmaceutical industry spanning operations, management, financing and therapeutics discovery and development.

Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer
April 19, 2016 | Seattle, Wash. Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drug combinations directly in patient tumors, will present preclinical data showing that the company’s clinical-stage oral CDK inhibitor, voruciclib, in combination with proteasome inhibitors, demonstrated superior tumor growth inhibition in xenografts than the single agents separately in a model of triple negative breast cancer (TNBC), a disease which has proven challenging to treat with standard chemotherapy options. The data are being presented today at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans.

Presage Biosciences Extends Research Collaboration with Takeda to Discover Novel Cancer Drug Combinations
April 14, 2016 | Seattle, Wash. Presage Biosciences, an oncology company that has established a novel drug development approach to assess drug combinations directly in patient tumors, announced today that is has entered into a multi-year extension of its November 2014 research alliance with Takeda Pharmaceuticals Company Limited (TSE: 4502).


Presage Biosciences Appoints Oncology Experts to Newly Created Medical Advisory Panel

January 11, 2016 | Seattle, Wash. Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the formation of a Medical Advisory Panel to provide guidance on research and development strategies for Presage’s portfolio of novel oncology therapies.

Presage Biosciences In-Licenses Clinical Stage Drug Program
November 24, 2015 | Seattle, Wash. Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that it has in-licensed voruciclib, its first clinical stage drug program. Voruciclib is an oral CDK inhibitor that has been in clinical development for cancer indications and will be developed in combination with other standard of care agents.

Presage Biosciences Appoints Two New Directors
November 24, 2015 | Seattle, Wash. Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Tachi Yamada and Christoph Lengauer to its board of directors.

Presage Biosciences Receives Strategic Investment 
from Takeda
August 20, 2015  | Seattle, Wash. Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, today announced that it has secured a strategic investment from Takeda Pharmaceutical Company Limited, through its venture capital arm, Takeda Ventures, Inc. Terms are not disclosed.


Study finds that microinjection platform enables assessment of multiple cancer drugs directly in tumors, predicts systemic response
April 22, 2015  | Seattle, Wash. A newly developed technology for simultaneously comparing response to multiple cancer drugs or combinations while a tumor is still in a patient’s body has been shown to accurately predict systemic response to the drugs, according to researchers at Fred Hutchinson Cancer Research Center and Presage Biosciences. The patented technology, called CIVO™, consists of an arrayed microinjection drug delivery device and quantitative analysis methodology.

Presage Biosciences Granted Sixth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor
SEATTLE, Wash. – March 20, 2015 – Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,926,567, covering the company’s CIVO™ arrayed microinjection platform.

Presage Biosciences Appoints Brad Margus to Board of Directors
SEATTLE, Wash. – March 16, 2015 – Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Brad Margus to its board of directors.  Margus is an accomplished entrepreneur and executive who brings broad and deep experience in the biopharmaceutical industry, particularly in building companies with novel science and managing these companies to create significant value.

Presage Biosciences Expands Collaboration with Takeda for CIVO™ Technology to Assess Cancer Drugs Directly in Solid Tumors
SEATTLE, Wash. – November 12, 2014 – Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human data much earlier in drug development and clinical trials, announced today that it has expanded its cancer research agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502).

Presage Biosciences Granted Fifth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor
SEATTLE, Wash. – October 21, 2014 – Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human efficacy data much earlier in drug development and clinical trials, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,834,428, covering the company’s CIVO™ arrayed microinjection platform.

Presage Biosciences Presents Proof-of-Concept Data for CIVO™ Preclinical Assessment Platform at AACR 2014 Annual Meeting
SEATTLE, Wash. – April 8, 2014 – Presage Biosciences, a biotechnology company focused on bringing the earliest human efficacy data possible into cancer drug development, presented preclinical data showing that microinjection of several standard-of-care cancer drugs using its CIVO™ arrayed microinjection platform correlated with drug effects on tumor growth mediated by conventional systemic dosing of the drugs in a poster session at the American Association for Cancer Research (AACR) 2014 Annual Meeting in San Diego.

Presage Biosciences Named a “Fierce 15” Biotech Company of 2013 by FierceBiotech
SEATTLE, Wash. – September 24, 2013 – Presage Biosciences, a leader in precision oncology, has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's eleventh annual Fierce 15 selection.

Presage Biosciences Announces First Patient in Clinical Trial of CIVO™ Precision Oncology
SEATTLE, Wash. – April 19, 2013 – Presage Biosciences, a leader in precision oncology, today announced the initiation of a clinical trial and the first patient use of CIVO™, the company’s precision oncology platform designed to improve treatment decisions for cancer patients. The single arm, non-therapeutic, observational study, being conducted at Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, is intended to evaluate the feasibility of Presage’s CIVO™ in assessing lymphoma response to multiple microinjected candidate chemotherapy agents.

Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
SEATTLE, Wash. – March 5, 2013 – Presage Biosciences, a leader in discovering effective cancer drug combinations, today announced that it has entered into a strategic collaboration agreement with Celgene Corporation under which Presage and Celgene will take advantage of Presage’s proprietary technology platform to identify novel drug combinations for solid tumor indications.

Presage Biosciences and Millennium Pharmaceuticals Enter Into Cancer Research Agreement
SEATTLE, Wash. and CAMBRIDGE, Mass. – April 5, 2012 – Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company. The research agreement will provide Millennium with access to Presage’s proprietary technology platform to enable non-clinical identification of effective novel oncology drug combinations in solid tumors.

Presage Biosciences Appoints Jim Towne as CEO
SEATTLE– December 15, 2011 – Presage Biosciences, a privately held biotechnology company that works with oncology-focused pharmaceutical companies through strategic alliances using its patented three-dimensional in vivo drug analysis platform, announced today that Caitlin Cameron has resigned as the CEO and director of Presage effective December 31, 2011. Jim Towne, a Presage Board member, was named as interim CEO. Ms. Cameron will continue to work closely with Presage leadership as an advisor.

Sign up for our mailing list
to be notified of relevant
Presage news.
(required)